Tenet Board Adds Two New Independent Directors

Go back to Tenet Board Adds Two New Independent Directors

UBS Reiterates Buy on Tenet Healthcare (THC) After Hosting Management Meetings

January 21, 2016 11:23 AM UTC

UBS maintained a Buy rating on Tenet Healthcare (NYSE: THC), and cut the price target to $51.00 (from $62.00), after meeting with management. THC reiterated that it expects to show solid growth in 2016 relative to its pro-forma 2015 EBITDA run rate of $2.3 bln. Consensus expectations call for just under $2.5... More

Mizuho Securities Upgrades Tenet Healthcare (THC) to Outperform

January 19, 2016 8:48 AM UTC

Mizuho Securities upgraded Tenet Healthcare (NYSE: THC) from Neutral to Outperform with a price target of $30.00 as two Glenview partners join the board.

Analyst Sheryl R. Skolnick commented, "Glenview's two HC partners are joining THC's Board and the firm can also appoint... More